Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial

Jingjing Li(Shenyang Ligong University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Weijing Sun(University of Kansas Medical Center), Xinbao Wang(Capital University), Qing Wei(Shanghai Tenth People's Hospital), Wei Wu(Anhui Agricultural University), Shurui Zhou(Zhejiang Cancer Hospital), Junrong Yan, Bingchen Wu(Hangzhou Hospital of Traditional Chinese Medicine), Yuhua Zhang(Zhejiang Cancer Hospital), Zhe Han(University of Maryland, Baltimore), Da Li(Sir Run Run Shaw Hospital), Yiwen Zhou(Weihai Maternal and Child Health Hospital), Qi Xu(Zhejiang Cancer Hospital), Cong Luo(Central South University), Qinhong Zheng(Quzhou City People's Hospital), Xing Sun, Yang Shao(Sanya University), Fabiao Zhang(Wenzhou Medical University), Xiaoqing Xu(Zhejiang Chinese Medical University)
Nature Communications
July 1, 2025
10.1038/s41467-025-60119-3
Cited by 12

Related Papers

Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384